CSF1R protein expression in reactive lymphoid tissues and lymphoma: Its relevance in classical Hodgkin lymphoma

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Martín Moreno, Ana M ^a   Roncador, Giovanna ^b   Maestre, Lorena ^b   Mata, Elena ^a   Jiménez, Scherezade ^b   Martínez Torrecuadrada, Jorge L ^b   Reyes García, Ana I ^b   Rubio, Carmen ^a   Tomás, José F ^a   Estévez, Mónica ^a   Pulford, Karen ^c   Piris, Miguel A ^d   García, Juan F ^a  

^a MD ANDERSON CANCER CENTER   (Spain)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD163 ANTIGEN; CD68 ANTIGEN; COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR 1 RECEPTOR; CYTOKINE RECEPTOR; LYSOZYME; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY FER216; STAT1 PROTEIN; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; COLONY STIMULATING FACTOR RECEPTOR;

ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; CELLULAR DISTRIBUTION; CLASSICAL HODGKIN LYMPHOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ANIMAL; GENETICS; HODGKIN DISEASE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LYMPHOID TISSUE; LYMPHOMA; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; GENE EXPRESSION; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LYMPHOID TISSUE; LYMPHOMA; MICE; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; SIGNAL TRANSDUCTION;

EID: 84935427360     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125203     Document Type: Article

References (46)

1. Kanzler H, Küppers R, Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med. 1996; 184: 1495-1505. PMID: 8879220
2. Steidl C, Connors JM, Gascoyne RD. Molecular Pathogenesis of Hodgkin's Lymphoma: Increasing Evidence of the Importance of the Microenvironment. J Clin Oncol. 2011; 29:1812-26. doi: 10.1200/JCO.2010.32.8401 PMID: 21483001
3. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood. 2002; 99: 4283-4297. PMID: 12036854
4. Alvaro T, Lejeune M, Salvado MT, Bosch R, Garcia JF, Jaén J, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res. 2005; 11: 1467-1473. PMID: 15746048
5. Muenst S, Hoeller S, Dirnhofer S, Tzankov A. Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival. Hum Pathol. 2009; 40: 1715-1722. doi: 10.1016/j.humpath.2009.03.025 PMID: 19695683
6. Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dirnhofer S. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica. 2008; 93: 193-200. doi: 10.3324/haematol.11702 PMID: 18223287
7. Sanchez-Aguilera A, Montalban C, de la Cueva P, Sanchez-Verde L, Morente MM, García-Cosío M, et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood. 2006; 108: 662-668. PMID: 16551964
8. Chetaille B, Bertucci F, Finetti P, Esterni B, Stamatoullas A, Picquenot JM, et al. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood. 2009; 113: 2765-3775. doi: 10.1182/blood-2008-07-168096 PMID: 19096012
9. Devilard E, Bertucci F, Trempat P, Bouabdallah R, Loriod B, Giaconia A, et al. Gene expression profiling defines molecular subtypes of classical Hodgkin's disease. Oncogene. 2002; 21: 3095-3102. PMID: 12082542
10. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010; 362:875-85. doi: 10.1056/NEJMoa0905680 PMID: 20220182
11. Jakovic LR, Mihaljevic BS, Perunicic Jovanovic MD, Bogdanovic AD, Andjelic BM, Bumbasirevic VZ. The prognostic relevance of tumor associated macrophages in advanced stage classical Hodgkin lymphoma. Leuk Lymphoma. 2011; 52:1913-9. doi: 10.3109/10428194.2011.580026 PMID: 21663512
12. Kamper P, Bendix K, Hamilton-Dutoit S, Honore B, Nyengaard JR, d'Amore F. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica. 2011; 96: 269-276. doi: 10.3324/haematol.2010.031542 PMID: 21071500
13. Sánchez-Espiridión B, Martin-Moreno AM, Montalbán C, Medeiros LJ, Vega F, Younes A, et al. Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma. Haematologica. 2012; 97: 1080-1084. doi: 10.3324/haematol.2011.055459 PMID: 22315492
14. Azambuja D, Natkunam Y, Biasoli I, Lossos IS, Anderson MW, Morais JC, et al. Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma. Ann Oncol. 2012; 23:736-42. doi: 10.1093/annonc/mdr157 PMID: 21602260
15. Agostinelli C, Gallamini A, Rigacci L, Vitolo U, Stracqualursi L, Piccaluga P, et al. The prognostic value of biologic markers in classical hodgkin lymphoma (CHL) patients. Ann Oncol. 2011; 22: 153-154.
16. Mantovani A, Schioppa T, Porta C, Allavena P, Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer metastasis rev. 2006; 25: 315-322. PMID: 16967326
17. Alvaro T, Lejeune M, Camacho FI, Salvado MT, Sanchez L, García JF, et al. The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma. Haematologica. 2006; 91: 1605-1612. PMID: 17145596
18. Farinha P, Masoudi H, Skinnider BF, Shumansky K, Spinelli JJ, Gill K, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood. 2005; 106: 2169-2174. PMID: 15933054
19. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004; 351: 2159-2169. PMID: 15548776
20. Canioni D, Salles G, Mounier N, Brousse N, Keuppens M, Morchhauser F, et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol. 2008; 26: 440-446. PMID: 18086798
21. Tang R, Beuvon F, Ojeda M, Mosseri V, Pouillart P, Scholl S. M-CSF (monocyte colony stimulating factor) and M-CSF receptor expression by breast tumour cells: M-CSF mediated recruitment of tumour infiltrating monocytes?. J Cell Biochem. 1992; 50: 350-356. PMID: 1334964
22. Pixley FJ, Stanley ER. CSF-1 regulation of the wandering macrophage: complexity in action. Trends Cell Biol. 2004; 14: 628-638. PMID: 15519852
23. Steidl C, Diepstra A, Lee T, Chan FC, Farinha P, Tan K, et al. Gene expression profiling of microdissected Hodgkin Reed Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. Blood. 2012; 120:3530-40. doi: 10.1182/blood-2012-06-439570 PMID: 22955918
24. Lamprecht B, Walter K, Kreher S, Kumar R, Hummel M, Lenze D, et al. Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. Nat Med. 2010; 16: 571, 579. doi: 10.1038/nm.2129 PMID: 20436485
25. Ullrich K, Wurster KD, Lamprecht B, Köchert K, Engert A, Dörken B, et al. BAY 43-9006/Sorafenib blocks CSF1R activity and induces apoptosis in various classical Hodgkin lymphoma cell lines. Br J Haematol. 2011; 155: 398-402. doi: 10.1111/j.1365-2141.2011.08685.x PMID: 21517818
26. Madan B, Goh KC, Hart S, William AD, Jayaraman R, Ethirajulu K, et al. SB1578, a novel inhibitor of JAK2, FLT3, and c-Fms for the treatment of rheumatoid arthritis. J Immunol. 2012; 189: 4123-4134. doi: 10.4049/jimmunol.1200675 PMID: 22962687
27. Domínguez-Soto A, Sierra-Filardi E, Puig-Kröger A, Pérez-Maceda B, Gómez-Aguado F, Corcuera MT, et al. Dendritic cell-specific ICAM-3-grabbing nonintegrin expression on M2-polarized and tumorassociated macrophages is macrophage-CSF dependent and enhanced by tumor-derived IL-6 and IL-10. J Immunol. 2011; 186: 2192-2200. doi: 10.4049/jimmunol.1000475 PMID: 21239715
28. Tan KL, Scott DW, Hong F, Kahl BS, Fisher RI, Bartlett NL, et al. Tumor-associated macrophages predict inferior outcomes in classical Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood. 2012; 120:3280-7. doi: 10.1182/blood-2012-04-421057 PMID: 22948049
29. Xu J, Escamilla J, Mok S, David J, Priceman S, West B, et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res. 2013; 73: 2782-2794. doi: 10.1158/0008-5472.CAN-12-3981 PMID: 23418320
30. He H, Xu J, Warren CM, Duan D, Li X, Wu L, et al. Endothelial cells provide an instructive niche for the differentiation and functional polarization of M2-like macrophages. Blood. 2012; 120: 3152-3162. doi: 10.1182/blood-2012-04-422758 PMID: 22919031
31. Pollard JW. Trophic macrophages in development and disease. Nat Rev Immunol. 2009; 9: 259-270. doi: 10.1038/nri2528 PMID: 19282852
32. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010; 141: 39-51. doi: 10.1016/j.cell.2010.03.014 PMID: 20371344
33. Lamagna C, Aurrand-Lions M, Imhof BA. Dual role of macrophages in tumor growth and angiogenesis. J Leukoc Biol. 2006; 80: 705-713. PMID: 16864600
34. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013; 19: 1423-1437. doi: 10.1038/nm.3394 PMID: 24202395
35. Sielska M, Przanowski P, Wylot B, Gabrusiewicz K, Maleszewska M, Kijewska M, et al. Distinct roles of CSF family cytokines in macrophage infiltration and activation in glioma progression and injury response. J Pathol. 2013; 230:310-21. doi: 10.1002/path.4192 PMID: 23520016
36. Espinosa I, Edris B, Lee CH, Cheng HW, Gilks CB, Wang Y, et al. CSF1 expression in nongynecological leiomyosarcoma is associated with increased tumor angiogenesis. Am J Pathol. 2011; 179: 2100-2107. doi: 10.1016/j.ajpath.2011.06.021 PMID: 21854753
37. Espinosa I, Beck AH, Lee CH, Zhu S, Montgomery KD, Marinelli RJ, et al. Coordinate expression of colony-stimulating factor-1 and colony-stimulating factor-1-related proteins is associated with poor prognosis in gynecological and nongynecological leiomyosarcoma. Am J Pathol. 2009; 174: 2347-2356. doi: 10.2353/ajpath.2009.081037 PMID: 19443701
38. Wei S, Nandi S, Chitu V, Yeung YG, Yu W, Huang M, et al. Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1 receptor-mediated regulation of myeloid cells. J Leukoc Biol. 2010; 88: 495-505. doi: 10.1189/jlb.1209822 PMID: 20504948
39. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006; 66: 605-612. PMID: 16423985
40. Hsu PL, Lin YC, Hsu SM. Expression of macrophage colony-stimulating factor (M-CSF) in two Hodgkin's Reed-Sternberg (H-RS) cell lines, HDLM-1 and KM-H2, and in H-RS cells in tissues. Int J Hematol. 1991; 54: 315-326. PMID: 1838015
41. Koh YW, Park C, Yoon DH, Suh C, Huh J. CSF-1R expression in tumor-associated macrophages is associated with worse prognosis in classical Hodgkin lymphoma. Am J Clin Pathol. 2014; 141: 573-583. doi: 10.1309/AJCPR92TDDFARISU PMID: 24619759
42. MacDonald KP, Palmer JS, Cronau S, Seppanen E, Olver S, Raffelt NC, et al. An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. Blood. 2010; 116: 3955-3963. doi: 10.1182/blood-2010-02-266296 PMID: 20682855
43. Wyckoff J, Wang W, Lin EY, Wang Y, Pixley F, Stanley ER, et al. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res. 2004; 64: 7022-7029. PMID: 15466195
44. Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 2013; 73: 1128-1141. doi: 10.1158/0008-5472.CAN-12-2731 PMID: 23221383
45. Manthey CL, Johnson DL, Illig CR, Tuman RW, Zhou Z, Baker JF, et al. JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Mol Cancer Ther. 2009; 8: 3151-3161. doi: 10.1158/1535-7163.MCT-09-0255 PMID: 19887542
46. Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, et al. Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy. Cancer Cell. 2014; 25: 846-859. doi: 10.1016/j.ccr.2014.05.016 PMID: 24898549